Literature DB >> 19836075

Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux.

Kit L Cheng, Judith Brody, Craig E Warshall, Elaine M Sloand, Steven L Allen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19836075      PMCID： PMC2826546          DOI： 10.1016/j.leukres.2009.09.024

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  8 in total

1.  Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletion.

Authors:  R J Garland; S J Groves; P Diamanti; S E West; K L Winship; P F Virgo; S P Robinson; A Oakhill; J M Cornish; D H Pamphilon; D I Marks; N J Goulden; C G Steward
Journal:  Bone Marrow Transplant       Date:  2005-08       Impact factor: 5.483

2.  Heparin-induced thrombocytopenia associated with fondaparinux.

Authors:  Theodore E Warkentin; Brian T Maurer; Richard H Aster
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

Review 3.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

Authors:  Russell P Rother; Leonard Bell; Peter Hillmen; Mark T Gladwin
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

Review 4.  Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Stephen J Richards; Peter Hillmen
Journal:  Br J Haematol       Date:  2007-05       Impact factor: 6.998

5.  CD55 and CD59 deficiency in transplant patient populations: possible association with paroxysmal nocturnal hemoglobinuria-like symptoms in Campath-treated patients.

Authors:  P Ruiz; D Weppler; P Tryphonopoulos; S Nishida; J Moon; T Kato; G Selvaggi; D Levi; J Madariaga; J DelaGarza; S Tuteja; M Garcia; A Tzakis
Journal:  Transplant Proc       Date:  2006 Jul-Aug       Impact factor: 1.066

6.  Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes.

Authors:  J Meletis; E Terpos; M Samarkos; C Meletis; E Apostolidou; V Komninaka; K Korovesis; D Mavrogianni; D Boutsis; E Variami; N Viniou; K Konstantopoulos; D Loukopoulos
Journal:  Hematol J       Date:  2001

7.  Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).

Authors:  Claire Hall; Stephen Richards; Peter Hillmen
Journal:  Blood       Date:  2003-07-31       Impact factor: 22.113

8.  Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Petra Muus; Ulrich Dührsen; Antonio M Risitano; Jörg Schubert; Lucio Luzzatto; Hubert Schrezenmeier; Jeffrey Szer; Robert A Brodsky; Anita Hill; Gerard Socié; Monica Bessler; Scott A Rollins; Leonard Bell; Russell P Rother; Neal S Young
Journal:  Blood       Date:  2007-08-16       Impact factor: 22.113
  8 in total
  3 in total

1.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

2.  Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.

Authors:  Yuzuru Kanakura; Kazuma Ohyashiki; Tsutomu Shichishima; Shinichiro Okamoto; Kiyoshi Ando; Haruhiko Ninomiya; Tatsuya Kawaguchi; Shinji Nakao; Hideki Nakakuma; Jun-ichi Nishimura; Taroh Kinoshita; Camille L Bedrosian; Keiya Ozawa; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2013-08-11       Impact factor: 2.490

3.  The Role of Whole-Body Magnetic Resonance Imaging (WB-MRI) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Authors:  Ferras Alashkar; Haemi Phaedra Schemuth; Felix Nensa; Juliane Göbel; Colin Vance; Michael Forsting; Ulrich Dührsen; Thomas Wilfried Schlosser; Alexander Röth
Journal:  Sci Rep       Date:  2018-09-07       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.